Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Year-over-year SG&A expense growth
Latest
23.79%
↑ 102% vs avg
Percentile
P72
Within normal range
Streak
4 qtr
Consecutive growthAccelerating
Average
11.79%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 23.79% |
| Q3 2025 | 20.12% |
| Q2 2025 | 10.95% |
| Q1 2025 | 5.66% |
| Q4 2024 | 2.39% |
| Q3 2024 | 11.16% |
| Q2 2024 | -5.87% |
| Q1 2024 | 6.26% |
| Q4 2023 | -4.03% |
| Q3 2023 | 3.42% |
| Q2 2023 | 2.41% |
| Q1 2023 | 10.85% |
| Q4 2022 | -34.92% |
| Q3 2022 | -3.40% |
| Q2 2022 | -3.32% |
| Q1 2022 | 37.70% |
| Q4 2021 | -35.77% |
| Q3 2021 | 114.41% |
| Q2 2021 | 10.30% |
| Q1 2021 | 87.21% |
| Q4 2020 | -39.38% |
| Q3 2020 | 34.66% |
| Q2 2020 | -34.49% |
| Q1 2020 | 49.94% |
| Q4 2019 | 5.04% |
| Q3 2019 | 113.52% |
| Q2 2019 | -9.92% |
| Q1 2019 | -12.98% |
| Q4 2018 | -4.59% |
| Q3 2018 | 39.96% |
| Q2 2018 | 25.05% |
| Q1 2018 | -16.42% |
| Q4 2017 | -53.87% |
| Q3 2017 | 143.09% |
| Q2 2017 | 6.60% |
| Q1 2017 | -57.01% |
| Q4 2016 | -34.81% |
| Q3 2016 | 43.58% |
| Q2 2016 | -12.82% |
| Q1 2016 | 27.05% |